



Half-Year Results FY2021

Half-Year Ended 31 December 2020



First Half Summary

Financials:

- Statutory loss attributable to:
 - Provision for impairment
 - Foreign exchange adjustments
 - One material loss in the period
 - Fewer completions in first half, in part due to impact of COVID-19 on US Court
- Foreign exchange adjustments are non-cash adjustments due to strengthening AUD:USD exchange rate, but translates into lower AUD commitments to funds for OBL contribution
- Net cash generated during period, from completions and collection of receivables
- Second half completions look strong, some of which are now unconditional, including AET estimated at \$22.0 million in revenue giving rise to material contingent assets
- LTCR remains reasonably consistent and higher than our historical LTCR
- Expenses have been flat during period, notwithstanding increase in headcount
- EPV growth of 11% in first half to \$17.6 billion with broad diversification of portfolio by geography and investment type

Non-Financial:

OBE:

- The acquired EMEA business has exceeded its first year new growth target by 80%, entitling the sellers to their full first year variable consideration payment
- The first variable consideration tranche was paid in full together with the first deferred but unconditional consideration amount on 4 December 2020
- Currently six co-funded matters between Funds 2 & 3 / 5 and 6 with aggregate EPV of \$550 million

Wivenhoe:

- Appeal scheduled for May 2021 if not settled before

Other:

- AFSL/MIS with up to five class actions either announced or in the pipeline
- Launched operations in NZ and commenced Latin America initiative

Westgem and Fund 4 Impairments

- Previously announced setbacks in two key investments that have been required to be impaired to comply with accounting standards. As both investments have positive prospects of success on appeal, commercially these investments are retained in full in our analysis of EPV.
- There is no cash impact for these impairments in this period.

Westgem

- Investment of A\$57.3 million that has been impaired, and a net provision of A\$6.7 million raised for potential adverse cost exposure.
- Senior counsel advice that the merits of the appeal are good. If appeals succeed, impairment and P&L impact will be reversed.
- The only future cash impact will be for uninsured adverse cost exposure on Westgem estimated to be A\$6.7 million plus the costs and adverse costs of the appeal if the appeals do not succeed.
- Appeal is likely to be heard in FY22.

Fund 4 Investment

- Investment of A\$53.6 million has been impaired, representing 8% of total fund size.
- Impairment raised as a consequence of an adverse decision on a motion for summary judgment.
- Investment was reviewed by external counsel, several internal lawyers and a former member of the judiciary experienced in the similar matters to the underlying dispute.
- Legal advice on prospects are positive, and expect to have appeal heard in 12 to 18 months. If appeal succeeds, impairment and P&L impact will be reversed.

Statutory Overview

	1HY 2021 \$m	2HY 2020 \$m	1HY 2020 \$m	2HY 2019 \$m
Litigation Contract Income	43.9	114.7	142.8	19.7
Revenue from cases	-	22.7	8.7	-
Litigation Expenses	(34.2)	(67.2)	(99.9)	(25.3)
Net gain / (loss) from investments	9.7	70.2	51.6	(5.6)
Management & Performance Fees	1.4	0.9	0.5	0.1
Other income (incl foreign exchange & interest)	5.0	21.5	2.5	3.7
Impairment	(107.0)	(15.8)	(1.4)	(7.7)
Other Net Operating Expenses	(63.3)	(37.0)	(45.8)	(23.6)
Share of loss in associates	(0.2)	(0.2)	0.0	0.0
Profit / (loss) on fair value of financial liabilities	10.1	2.1	(15.7)	0.0
Income tax benefit / (expense)	33.5	(13.4)	(2.5)	7.4
Profit / (loss) after tax	(110.8)	28.3	(10.8)	(25.7)
Other comprehensive income / (loss)	(42.5)	(15.5)	8.6	(1.2)
Total comprehensive income / (loss)	(153.3)	12.8	(2.2)	(26.9)
Cash and cash equivalents	167.9	194.4	262.7	226.5
Receivables from litigation contracts	81.7	134.7	79.0	16.9
Cash and net receivables	249.6	329.1	341.7	243.4
Litigations in Progress (intangible assets)	399.9	517.2	514.6	427.0
Other litigation investment assets	125.9	110.7	105.6	0.0
Net Asset	651.2	767.2	758.4	515.5
Number of shares	262.2	249.4	249.4	204.6
Net Asset Backing (\$ per share)	2.5	3.1	3.0	2.5
Estimated Portfolio Value (\$BN) ¹	17.6	15.8	11.5 ²	9.5
Number of investments ¹	315	304	338	94


1. Includes funded, conditionally funded and IC approved investments

2. Does not include an EPV for the acquired Omni Bridgeway business

Sources and Applications of Cash

	1HY 2021 \$m	2HY 2020 \$m	1HY 2020 \$m	2HY 2019 \$M
Cash generation				
Proceeds: – from litigation funding	97.3	80.0	91.0	19.3
Proceeds: – from claims portfolio investments	8.2	6.3	8.7	-
Proceeds: – from disposal of a financial asset	-	9.7	-	-
NCI contribution to Fund 6 costs	4.8	2.3	2.2	-
Net interest	(3.8)	(0.7)	(3.9)	(2.2)
Other income	0.4	-	0.8	-
Movement in receivables balance	(53.0)	55.7	62.2	6.3
	53.9	153.3	161.0	23.4
Cash burn				
Operational cash expenditure	(39.9)	(37.0)	(31.6)	(37.3)
Transaction costs – purchase of OB (one-off)	-	-	(4.8)	-
Professional advisors (one-off)	-	-	(0.3)	-
Income tax received / (paid)	(7.5)	(3.9)	-	4.6
	(47.4)	(40.9)	(36.7)	(32.7)
Net Cash generation	6.5	112.4	124.3	(9.4)
Cash and receivables balance				
Cash: – direct balance sheet	109.8	133.2	168.3	133.1
Cash: – consolidated funds	58.1	61.2	94.4	93.4
Receivables balance: – direct balance sheet	49.3	73.2	45.8	16.0
Receivables balance: – consolidated funds	32.4	61.5	33.2	0.9
Total Cash and Receivables Balance	249.6	329.1	341.7	243.4

- IFRS reporting does not necessarily represent the cash generating capacity of the business given revenue recognition principles and capitalisation of certain expenses into intangibles.
- Net cash generation identifies cash inflows from completions and receivables and deducts cash expenses during the period.



Net cash generation is categorised as non-IFRS information prepared in accordance with ASIC Regulatory Guidance 230 – Disclosing non-IFRS financial information, issued in December 2011. This information has not been audited or reviewed.


Operating Expenditure (excluding impairments)

	1HY 2021 \$m	2HY 2020 \$m	1HY 2020 \$m	2HY 2019 \$m
As per Profit and Loss Statement				
Claims portfolio expense	(0.6)	(8.3)	(6.2)	-
Finance costs	(0.3)	(0.3)	(1.0)	(0.1)
Depreciation expense	(1.7)	(1.6)	(1.3)	(0.3)
Employee benefits expense	(28.5)	(32.6)	(17.7)	(14.4)
Corporate and office expense	(8.0)	(8.3)	(11.7)	(7.3)
Other expenses	(24.2)	(0.3)	(7.8)	(9.2)
	(63.3)	(51.4)	(45.7)	(31.3)
Include: Capitalised items				
Capitalised items				
- employee costs	(5.0)	(6.4)	(4.0)	(3.7)
- borrowing costs	(4.6)	(4.7)	(5.7)	(5.9)
- overheads	(0.3)	(0.3)	(0.2)	(0.6)
	(9.9)	(11.4)	(9.9)	(10.2)
Deduct: Non-cash items & one-offs				
Claims portfolio expense	0.6	8.3	6.2	-
NCI contribution to Fund 6 costs	-	1.2	3.3	-
Transaction costs – purchase of OB	-	-	4.8	-
Professional advisors	-	-	0.3	-
Adverse costs provision	13.9	-	4.3	0.6
LTIP	8.9	6.3	2.8	3.3
STIP – accrued and unpaid	-	9.7	-	-
Depreciation expense	1.7	1.6	1.3	0.3
Net foreign exchange loss	8.2	(1.3)	1.3	-
	33.3	25.8	24.3	4.2
Operational Cash Expenditure	(39.9)	(37.0)	(31.3)	(37.3)
% of net assets	5.7%	4.8%	4.1%	7.2%
% of investments	6.0%	5.6%	4.9%	8.6%
% of EPV	0.2%	0.2%	0.3%	0.4%
Headcount	172	163	145	101
Number of offices	18	18	18	14


- Operating expenditure has remained reasonably flat from last half.
- Significant increase in other expenses relates to adverse cost provision, some of which may reverse and foreign exchange loss, both of which were non-cash expenses in the half.
- Decrease in employee costs, both expensed and capitalised, relates to no accrual for STIP.

Balance Sheet Strength and Investment Portfolio

Cash and Net Receivables (\$m)




Net Assets (\$m)¹




1. Excluding impairments, the Net Assets as at FY19, FY20 and HY21 are \$515.5m, \$767.2m and \$651.2m.

Investments (\$m)^{1,2}



Portfolio (EPV) (\$b)¹




1. Excluding impairments, the EPV at HY21 is \$16.0b.

1. Investments in Fund 6 includes \$90.9m of fair value adjustments on acquisition.
 2. Excluding impairments in accordance with accounting standards, Investments at FY19, FY20 and HY21 are \$427.0m, \$627.9m and \$525.8m.


Movements in Investments

- The decrease in intangibles carrying value is attributable to the two material impairments, derecognition of completed matters and FX adjustments
- During the period the net increase of new investments and additions to existing investments exceeded completions by a ratio of almost 2:1
- This reflects a growth in the investment base but also a lack of completions



Conversion rates and EPV on completions

Long term conversion rate and EPV (\$b)^{1,2}



- LTCR after losses has remained above our historical LTCR over the past several periods
- EPV conversion has been lumpy throughout the period, reflecting the transition from balance sheet investor to fund manager and the duration of the underlying investments

1. HY 21 EPV and conversion rate excludes US investment that was paid out early
2. The analysis does not include any impaired assets which are ongoing investments and therefore do not impact LCTR

Actual and anticipated revenue from completions to date

	EPV A\$m	Possible Completion EPV A\$m			
		FY2021	FY2022	FY2023	FY2024+
Balance Sheet	1,063.2	469.5	335.2	257.6	0.9
Fund 1	2,384.3	67.7	1,756.7	291.7	268.2
Funds 2 & 3	2,970.8	249.1	1,514.0	1,177.5	30.2
Fund 4	3,345.6	24.3	108.5	2,444.2	768.6
Fund 5	2,769.2	254.3	836.3	518.8	1,159.8
Fund 6	2,473.8	201.4	449.2	831.0	992.2
Fund 7	N/A	-	-	-	-
Total	15,006.9	1,266.3	4,999.9	5,520.8	3,219.9


- 2H21 completions are spread between funds and balance sheet, with the single largest contribution from Wivenhoe
- US completions in Funds 1 and 4 for 2H21 have been scaled back to reflect continuing delays in US Court processes
- Balance sheet investments anticipated to run-off completely by FY24, with material completions in first-gen funds in FY22, but may be subject to further risk of delay in the US

Income AUD million	Balance Sheet	Funds						Total
		1	2 & 3	4	5	6	7	
FY 2021								
Recognised income								
Completed investments	15.4	0.7	17.4	2.5	-	0.6	-	36.6
Ongoing investments	0.2	4.5	-	-	-	2.6	-	7.3
Total income recognised FY2021	15.6	5.2	17.4	2.5	-	3.2	-	43.9
Income yet to be recognised ^C								
Agreed in-principle settlements ^C	1.9	3.9	-	-	-	-	-	5.8
Binding conditional settlements ^C	-	-	-	-	-	-	-	-
Successful judgements ^C	192.0	-	-	-	20.4	-	-	212.4
Other ^C	-	7.7	-	-	-	-	-	7.7
Total income yet to be recognised ^C	193.9	11.6	-	-	20.4	-	-	225.9


C. Subject to change

Total Portfolio Diversification

EPV by Geography



EPV by Investment Type



Fund Summary

	Fund size	Committed	Investors		Omni Bridgeway		EPV A\$m	Possible Completion EPV A\$m				#	\$ Weighted average (%)	Legal outcome (%)	ROIC (excl. overheads (%))	IRR (excl. overheads (%))
			Capital A\$m	Returns A\$m	Capital A\$m	Fees A\$m		FY2021	FY2022	FY2023	FY2024+					
Fund 1	USD 172m	100%	72.1	44.2	54.3	6.5	2,384.3	67.7	1,756.7	291.7	268.2	28	66.7	85.7	14.6	13.0
Funds 2 & 3	AUD 180m	96%	39.6	24.1	20.2	2.1	2,970.8	249.1	1,514.0	1,177.5	30.2	32	54.0	81.8	101.0	190.0
Fund 4	USD 500m	26%	105.1	25.3	26.2	6.2	3,345.6	24.3	108.5	2,444.2	768.6	11	100.0	100.0	21.9	201.0
Fund 5	USD 500m	35%	51.3	-	12.9	-	2,769.2	254.3	836.3	518.8	1,159.8	36	N/A	N/A	N/A	N/A
Fund 6	EUR 150m	97%	104.8	41.3	5.3	2.2	2,473.8	201.4	449.2	831.0	992.2	192	73.3	65.0	330.2	158.3
Fund 7	USD 100m	4%	1.3	-	3.3	-	N/A	-	-	-	-	2	N/A	N/A	N/A	N/A
Fund Total			374.2	134.9	122.2	17.0	13,943.7	796.8	4,664.7	5,263.2	3,219.0	301.0				

As noted on slide 3, due to the advice received on future prospects, Omni Bridgeway has not reduced the EPV of the Fund 4 investment which has been impaired in the statutory accounts

First Generation Funds

We have been asked how we analyse the ability of the first generation funds to return value to OBL shareholders based on their current portfolios and returns to date. **Whilst Omni Bridgeway does not provide earnings guidance or forecasts and notes that past performance is not necessarily an indicator of future performance**, we explain how we analyse these funds.

Omni Bridgeway assessment process:

- Preferred capital and returns (non-recourse)
- Fund portfolio EPV and the Long Term Conversion Rate (LTCR)
- Fund ROIC and deployed capital
- Possible completion periods

Preferred Capital and Returns

Fund 1

as at 31 December 2020	Total \$m	Accumulated \$m
Preferred Capital	72.1	72.1
Accumulated Preferred Return	41.9	114.0
Accumulated Special Distribution	2.3	116.3

Funds 2 & 3

as at 31 December 2020	Total \$m	Accumulated \$m
Preferred Capital	39.6	39.6
Accumulated Preferred Return	19.8	59.4
Accumulated Special Distribution	4.3	63.7

First Generation Fund EPV¹ and LTCR

	# investments	EPV \$m	Possible Completion EPV			
			FY2021 \$m	FY2022 \$m	FY2021 \$m	FY2021 \$m
Fund 1	28	2,384.3	67.7	1,756.7	291.7	268.2
Funds 2 & 3	29	2,970.8	249.1	1,514.0	1,177.5	30.2
Total	57	5,355.1	316.8	3,270.7	1,469.2	298.4

Global LTCR at 31 December 2020 was 15% of EPV.

- Sufficient headroom in each fund to return capital and distribute preferred returns to investors, distribute capital and fees to the manager and provide material return to investors on profit splits of 85:15 to OBL in Fund 1, and 80:20 to OBL in Funds 2 & 3
- Derecognised from the Fund 2 & 3 EPV and not included in the above accumulated returns, there was \$16.9m receivable from litigation contracts to be distributed to investors upon collection.

1. Includes funded investments only

Outlook

- Key focus areas for next half include:
 - Continued geographic and product expansion consistent with our five-year plans
 - Consideration of follow on fund for Fund 6 given current capacity
 - Continuing consideration of a potential change of listing venue
- Possible relocation to the US in April 2021

Disclaimer

- The material in this presentation has been prepared by Omni Bridgeway and is general background information about Omni Bridgeway's activities. The information is given in summary form and does not purport to be complete.
- A number of terms used in this presentation including: ROIC, EPV, net cash generation, operational cash expenditure, success rate on dollar weighted average, IRR and actual commitments are categorised as non-IFRS information prepared in accordance with ASIC Regulatory Guidance 230 – Disclosing non-IFRS financial information, issued in December 2011. This information has not been audited or reviewed by EY unless expressly stated. For further commentary and analysis refer to Omni Bridgeway's FY21 Half Yearly report.
- This presentation is provided for general information purposes. The information in this presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase any Omni Bridgeway securities. Neither the information in this presentation nor any part of it shall form the basis of or be relied upon in connection with any future offer of Omni Bridgeway securities or act as an inducement to enter into any contract or commitment whatsoever.
- To the maximum extent permitted by law, no representation or warranty is given, express or implied, as to the accuracy of the information contained in the presentation.
- The information in this presentation is not investment advice and has been prepared without taking into account your investment objectives, financial situation or particular needs (including financial and taxation issues). It is important that you read and consider the terms of any Omni Bridgeway securities in full before deciding to invest in such securities and consider the risks that could affect the performance of those securities.
- If you have any questions, you should seek advice from your financial adviser or other professional adviser before deciding to invest in Omni Bridgeway securities.
- By providing the material in this presentation Omni Bridgeway is not in any way making forecasts, predictions or providing earnings guidance and nothing in this presentation should be relied on as doing so.
- This presentation is authorised for release by the disclosure committee.

This presentation is for the use for Omni Bridgeway's public shareholders and is not an offering of any Omni Bridgeway private fund.

Risk Mitigation

Risk	Potential impact	Strategic response
PORTFOLIO CONCENTRATION	<p>Potential for a funded case to be lost = Omni Bridgeway investment lost and exposure to adverse costs</p> <p>Two material investment risks on balance sheet: Wivenhoe Dam & Westgem</p>	<ul style="list-style-type: none"> • Deliberate transition from idiosyncratic risk to systemic risk of a portfolio • Portfolio represents increased number of investments, broader range of case types, sizes and jurisdictions • Co-funding and ACO insurance cover in place
COMPETITION	<p>Price compression</p> <p>Loss of market share</p> <p>Talent loss</p>	<ul style="list-style-type: none"> • Market differentiation (track record, capital adequacy, ACO cover, security for costs, transparency through public listing, reputation for integrity and fairness, strategic insights & project management on cases) • Innovation - products & services • Know-how - business processes • Talent retention strategies • Taking steps to reduce cost and increase availability of capital
REGULATORY CHANGE	<p>Need to adjust business model</p> <p>New reporting /licensing regime</p> <p>New market entrants</p>	<ul style="list-style-type: none"> • Awareness, involvement and industry leadership
KEY-PERSON DEPENDENCY	<p>Loss of know-how</p>	<ul style="list-style-type: none"> • Legal avenues: non-compete, confidentiality and IP protection agreements • Talent retention & knowledge transfer strategies: coaching, mentoring, professional development to build, transfer and safe-guard corporate knowledge • Incentive plans which reward loyalty and engagement • Purchase agreement structured to retain key executives
IT & DATA SECURITY	<p>Loss of data due to software or hardware failure</p> <p>Theft or corruption of data or trade secrets due to social engineering or external penetration ('hacking')</p>	<ul style="list-style-type: none"> • Continuous adaptation to be nimble • Audits by external security and IT providers • Staff education • Constant vigilance
BRAND REPUTATION	<p>If reputation is sullied, stakeholder trust and loyalty is eroded and brand equity and financial value can be compromised</p>	<ul style="list-style-type: none"> • Conscious culture of risk management • Numerous policies and practices to safe- guard reputation including escalation procedures throughout our organisation and regular and clear communication with all stakeholders
POOR INVESTMENT DECISIONS	<p>Financial impact of loss of investment, and in relevant jurisdiction adverse cost exposure, with flow on reputation risk</p>	<ul style="list-style-type: none"> • Investment in experienced investment managers with litigation experience • Enhanced Investment Committee process with introduction of external resources from the judiciary and legal profession

The above is not intended to be an exhaustive list of all the risks faced by the business.

Glossary of Terms and Notes

ESTIMATED PORTFOLIO VALUE (EPV)	<p>EPV for an investment where the funding entity earns:</p> <ul style="list-style-type: none"> (i) a percentage of the resolution proceeds as a funding commission, is the current estimate of the investment's recoverable amount after considering the perceived capacity of the defendant to meet the claim and any other pertinent factors. Such amount is not necessarily the amount being claimed by the claimants, nor is it an estimate of the return to the group if the investment is successful, (ii) a funding commission calculated as a multiple of capital invested, is arrived at by taking the estimated potential income return from the investment and grossing this up to an EPV using the Long-Term Conversion Rate, and (iii) a funding commission calculated on a combination of the above bases or on an alternative basis, may utilise one of the above methodologies, or a hybrid construct, or an alternative methodology depending upon the components of the funding commission. <p>OBE Group's EPV has been estimated on a conceptually consistent basis; enforcement case investments may have a multi-layered approach from a timing and value perspective. Where OBE Group have not yet been able to ascertain an EPV consistent with the disclosed methodology an EPV of zero has been used.</p> <p>How ever calculated, an EPV is an estimate and is subject to change over time for a number of reasons, including, but not limited to, changes in circumstances and knowledge relating to an investment or the defendant(s) perceived capacity to meet the claim, partial recovery and, where applicable, fluctuations in exchange rates between the applicable local currency and the Australian dollar. Possible EPV's are reviewed and updated where necessary.</p> <p>The portfolio's value is the aggregation of individual investments' EPV's as determined above.</p>
IFRS	International Financial Reporting Standards
IRR	Internal Rate of Return
LTIP	Long Term Incentive Program
NCI	Non-Controlling Interest
OBE GROUP	Omni Bridgeway Holding B.V. (ie 'Omni Bridgeway Europe'), Omni Bridgeway AG (formerly ROLAND ProzessFinanz), and a joint venture with IFC (part of the World Bank Group).
PAST PERFORMANCE	Past performance is <u>not necessarily an indication</u> of future performance. Past performance indicates that Omni Bridgeway's litigation funding investments (excluding Omni Bridgeway Europe's investments) have generated average gross income of approximately 15% of the EPV of an investment at the time it is completed (Long-Term Conversion Rate). The Long-Term Conversion Rate, ROIC and IRR from completed investments may vary materially over time. By providing this information, Omni Bridgeway has not been and is not now, in any way, providing earnings guidance for future periods.
POSSIBLE COMPLETION PERIODS	The possible completion period is Omni Bridgeway's current estimate of the period in which an investment may be finalised. Currently, estimating the completion periods for investments is subject to material uncertainty caused by the COVID-19 pandemic and its impact on court schedules and arbitration timings in various jurisdictions. The " <i>Possible Completion Period</i> " is <u>not</u> a projection or forecast. An investment may finalise earlier or later than the identified period for various reasons. Completion for these purposes means finalisation of the litigation by either settlement, judgement or arbitrator determination, for or against the funded claimant, notwithstanding that such finalisation may be conditional upon certain matters such as court approval in the context of a class action. It may not follow that the financial result will be accounted for in the year of finalisation. Possible completion period estimates are reviewed and updated where necessary. Currently, estimating the completion periods for investments is subject to additional uncertainty caused by the COVID-19 pandemic and its impact on court schedules and arbitration timings in various jurisdictions.
ROIC	Return on Invested Capital - gain or loss on derecognition of investments (including or excluding overheads) divided by the total spent on investments (including or excluding overheads)
STIP	Short Term Incentive Program

ASIA	AUSTRALIA		CANADA	EUROPE, MIDDLE EAST & AFRICA			UNITED STATES OF AMERICA	
<p>Hong Kong +852 3978 2629 Level 27 World-Wide House 19 Des Voeux Road Central Central, Hong Kong</p> <p>Singapore +65 6813 2647 Level 13-03 6 Battery Road Singapore 049909</p>	<p>Adelaide +61 8 8122 1010 50 Gilbert Street Adelaide SA 5000</p> <p>Brisbane +61 7 3108 1311 Level 54 111 Eagle Street Brisbane QLD 4000</p> <p>Melbourne +61 3 9913 3301 Level 3 Bourke Place 600 Bourke Street Melbourne VIC 3000</p>	<p>Perth +61 8 9225 2300 Level 6 37 St Georges Terrace Perth WA 6000</p> <p>Sydney +61 2 8223 3567 Level 18 68 Pitt Street Sydney NSW 2000</p>	<p>Montreal +1 514 257 6971 60 rue St-Jacques Bureau 401 Montréal QC H2Y 1L5</p> <p>Toronto +1 416 583 5720 250 The Esplanade Suite 127 Toronto ON M5A 1J2</p>	<p>Amsterdam +31 70 338 4343 Schiphol Boulevard 121 1118 BG Schiphol Amsterdam The Netherlands</p> <p>Cologne +49 221 801155-0 Gereonstr. 43-65 50670 Cologne Germany</p>	<p>Geneva +41 22 818 6300 Rue de la Rôtisserie 4 1204 Geneva Switzerland</p> <p>London +44 203 968 6061 81 Chancery Lane London WC2A 1DD United Kingdom</p>	<p>Dubai +971 4 514 4608 Unit 1905, Level 19 Index Tower Dubai International Financial Centre 507152 Dubai United Arab Emirates</p>	<p>Houston +1 713 965 7919 LyondellBasell Tower 1221 McKinney Street Suite 2860 Houston TX 77010</p> <p>Los Angeles +1 213 550 2687 555 W. Fifth Street Suite 3310 Los Angeles CA 90013</p>	<p>New York +1 212 488 5331 437 Madison Avenue 19th Floor New York NY 10022</p> <p>San Francisco +1 415 231 0363 50 California Street Suite 2550 San Francisco CA 94111</p>